Tisagenlecleucel (CTL019) 是一种自体抗 CD19 嵌合抗原受体 (CAR) T 细胞疗法。Tisagenlecleucel 靶向并消除表达 CD19 的 B 细胞。Tisagenlecleucel 可用于难治性侵袭性弥漫性大 B 细胞淋巴瘤的研究。
| 生物活性 | Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma[1][2]. |
体内研究
(In Vivo) | Tisagenlecleucel 靶向并清除表达 CD19 的 B 细胞，显示出对 B 细胞淋巴瘤的疗效[1]。
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com